文献速递免疫规划传染病防控与疫情报告

丹麦16-65岁公民接种COVID-19疫苗后即时不良反应调查

Immediate adverse reactions following COVID-19 vaccination among 16-65-year-old Danish citizens.
PubMed 文献 · Vaccine · 2023-06-23

本研究基于丹麦人群队列BiCoVac,估计16-65岁公民接种COVID-19疫苗后20种自报即时不良反应的频率及数量分布。共邀请889,503人,171,008人(19%)纳入分析。结果显示女性、年轻人群及既往感染者更可能报告不良反应,但大多数丹麦公民未出现即时不良反应。

要点

  • 第一剂后最常见不良反应为注射部位红肿和/或疼痛(20%),第二、三剂后为疲倦(22%和14%)。
  • 26-35岁、女性及既往COVID-19感染者更可能报告不良反应。
  • 第一剂后ChAdOx1-2(AstraZeneca)接种者报告不良反应多于其他疫苗类型。

核心结论

  • 即时不良反应频率在女性和年轻人群中最高,但大多数丹麦公民接种COVID-19疫苗后未出现即时不良反应。

研究设计与样本

  • 研究使用丹麦人群队列研究BiCoVac的数据,估计20种自报不良反应的频率,按性别、年龄和疫苗类型分层分析每一剂次。
  • 共邀请889,503名公民,171,008名(19%)接种者纳入分析。

主要发现

  • 第一剂后最常见不良反应为注射部位红肿和/或疼痛(20%),第二剂和第三剂后为疲倦(分别为22%和14%)。
  • 26-35岁个体、女性及既往COVID-19感染者分别相比更年长个体、男性及无既往感染者更可能报告不良反应。
  • 第一剂后,接种ChAdOx1-2(AstraZeneca)者相比接种其他疫苗类型者报告更多不良反应。
  • 第二剂和第三剂后,接种mRNA-1273(Moderna)者相比接种BNT162b2(Pfizer-BioNTech)者报告更多不良反应。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: There is sparse knowledge of immediate adverse reactions following COVID-19 vaccination. OBJECTIVE: This study aimed to estimate the frequency and number of immediate adverse reactions following COVID-19 vaccination in a Danish population. METHODS: The study used data from the Danish population-based cohort study BiCoVac. The frequencies of 20 self-reported adverse reactions were estimated for each vaccine dose stratified by sex, age, and vaccine type. Also, the distributions of number of adverse reactions following each dose were estimated stratified by sex, age, vaccine type, and prior COVID-19 infection. RESULTS: A total of 889,503 citizens were invited and 171,008 (19 %) vaccinated individuals were included in the analysis. The most frequently reported adverse reaction following the first dose of COVID-19 vaccine was redness and/or pain at the injection site (20 %) while following the second and third dose, tiredness was the most frequently reported adverse reaction (22 % and 14 %, respectively). Individuals aged 26-35 years, females, and those with a prior COVID-19 infection were more likely to report adverse reactions compared with older individuals, males, and those with no prior COVID-19 infection, respectively. Following the first dose, individuals vaccinated with ChAdOx1-2 (AstraZeneca) reported more adverse reactions compared with individuals vaccinated with other vaccine types. Individuals vaccinated with mRNA-1273 (Moderna) reported more adverse reactions following the second and third dose compared with individuals vaccinated with BNT162b2 (Pfizer-BioNTech). CONCLUSION: The frequency of immediate adverse reactions was highest among females and younger persons, however, most of the Danish citizens did not experience immediate adverse reactions following COVID-19 vaccination.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Torp Hansen K, Kusk Povlsen F, Hammer Bech B, et al. Immediate adverse reactions following COVID-19 vaccination among 16-65-year-old Danish citizens. Vaccine. 2023. PMID: 37391313. doi:10.1016/j.vaccine.2023.06.069

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。